Project Grant R01AI192512
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $2.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rhode Island, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $721,365 to the University of California Irvine on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a single-dose influenza vaccine platform that extends immune response breadth against viral variants. The funded research combines nanoparticles presenting H5 hemagglutinin antigen with thermo-responsive polymer depots that release antigen slowly, extending exposure time to elicit...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $127,932 on March 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate neuraminidase as a target antigen for a universal influenza virus vaccine. The research addresses the gap between current seasonal influenza vaccines, which elicit only strain-specific immunity with variable effectiveness and provide no protection against novel pandemic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
- The National Institute of Allergy and Infectious Diseases awarded the Board of Regents of the University of Nebraska $799,792 on April 1, 2026, to develop universal influenza vaccine immunogens under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of a novel vaccine that combines the immunodominant HA1 head domains from EPIGRAPH-designed genes with conserved HA2 stalk domains from consensus immunogens. The research integrates five complementary...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Washington University $765,798 on September 3, 2026, to develop a mucosal H5 influenza virus vaccine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop a single-dose mucosal vaccine using a chimpanzee adenovirus vectored platform to confer robust protection against high-dose H5N1 challenge and transmission in pre-clinical...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $703,187 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI201207) to advance understanding of antigenically complex hemagglutinin vaccine formulation requirements and mechanisms of protection in universal influenza vaccine development. The research addresses a core limitation of current influenza vaccines: they induce responses primarily against...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $695,041 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms underlying combination adjuvant-driven improvement of influenza vaccine responses. The research defines the innate immune signatures and adaptive immune responses elicited by existing and novel combination adjuvants as they relate to driving immune responses directed against influenza virus...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $661,313 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support development of a pan-influenza A vaccine. The research, led by Dr. Daniel Lingwood at the Ragon Institute of MGH, MIT and Harvard, focuses on elicitation of broadly neutralizing antibodies that protect against all influenza A viruses by triggering...